Page 45 - Demo

Panitumumab and chemoradiation for inoperable pancreatic cancer432Supplementary TablesSupplementary Table 1Suplementary Table 1. Adverse events during chemoradiation with panitumumab, according to CTCAE criteria (after 43 days) Cohort 1.0 mg/kg (n=3) Cohort 1.5 mg/kg (n=6) Cohort 2.0 mg/kg (n=5)AE, n (%) Grade 1/2 Grade 3/4 Grade 1/2 Grade 3/4 Grade 1/2 Grade 3/4BLOOD/ BONE MARROWThrombocytopenia - - - 2 (33) 1 (20) -Anemia 2 (67) - 2 (33) - - -Neutropenia - 1 (33) - 3 (50) - -METABOLIC/LABORATORYCreatinine increase 1 (33) - - - - -CONSTITUTIONAL SYMPTOMSFatique 1 (33) - 5 (83) 1 (17) - -Fever 3 (100) - 1 (17) - 1 (20) -NEUROLOGYNeuropathy 1 (33) - - - - -SYNDROMESFlu like syndrome 1 (33) - - - 2 (40) -PULMONARY/UPPER RESPIRATORYDyspnea 1 (33) - - - - -LYMPHATICSEdema 2 (67) - - - -GASTROINTESTINALNausea 2 (67) - 2 (33) - 1 (20) -Vomiting - - 3 (50) - - -Anorexia 1 (33) - 4 (67) - - -Ascites (non malignant) - - - 1 (17) - -Flatulence 1 (33) - - - - -HEMORRHAGE/BLEEDINGGastrointestinal bleeding - - - 1 (17) - -PAINHeadache 1 (33) - 1 (17) - - -Pain feet - - 1 (17) - 1 (20) -Muscle pain - - 1 (17) - - -DERMATOLOGY/SKINDry blister - - 1 (17) - - -Acneiform rash 1 (33) - 1 (17) - 3 (60) -Hair loss/ alopecia - - 1 (17) - - -INFECTIONUrinary tract infection - - 1 (17) - - -Pneumonia - - 1 (17) - - -Supplementary Table 2Cohort Mean (median) tumor size (mm)* Standard error of mean (mm)1 mg/kg 37 (33) 111,5 mg/kg 43 (38) 82 mg/kg 43 (36) 16*Longest diameter of measurable primary tumor